Welcome to our dedicated page for Aerie Pharmaceut news (Ticker: AERI), a resource for investors and traders seeking the latest updates and insights on Aerie Pharmaceut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aerie Pharmaceut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aerie Pharmaceut's position in the market.
Aerie Pharmaceuticals (NASDAQ: AERI) has announced the commencement of its Phase 3 clinical trial, COMET-2, for AR-15512, a novel treatment for Dry Eye Disease (DED). This marks the first participant's enrollment in a series of three studies aimed at supporting a New Drug Application (NDA) by 2024. Approximately 460 participants will be evaluated for efficacy using the Schirmer test and SANDE questionnaire over three months. Topline results are anticipated in late 2023, following previous promising results from the COMET-1 study.
Aerie Pharmaceuticals (NASDAQ: AERI) reported a strong performance for Q1 2022, with net revenues from its glaucoma franchise reaching $29.8 million, a 30% increase from Q1 2021. The company reaffirmed its 2022 revenue guidance for the glaucoma franchise at $130 million to $140 million. Despite a net loss of $35.9 million, improved from $42.0 million last year, Aerie's liquidity remains strong, with $199.2 million in cash and investments. The company is on track for its Phase 3 trial enrollment of AR-15512 and aims to reduce cash usage by 15% in 2022.
Aerie Pharmaceuticals (NASDAQ: AERI) will announce its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will take place at 5:00 p.m. ET to discuss the results and update on business developments. Aerie focuses on innovative ophthalmic therapies for eye diseases, with products like Rhopressa® and Rocklatan® targeting conditions such as glaucoma and ocular hypertension. Further information will be available on its investor relations website.
Aerie Pharmaceuticals (AERI) announced the presentation of fourteen abstracts at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 1-4, 2022, in Denver, Colorado. These abstracts pertain to Aerie's Rhopressa®/netarsudil, AR-15512, and the "ROCK’Sters" program. Notable highlights include data from independent studies on netarsudil's real-world applications, preclinical results extending potential uses, and the Phase 2b study results for AR-15512 focusing on dry eye symptoms. Aerie aims to expand the clinical utility of its innovative treatments for ocular conditions.
Aerie Pharmaceuticals (NASDAQ: AERI) announced three significant presentations at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 from
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced participation in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET. CEO Raj Kannan, CFO Peter Lang, and CMO Dr. Gary Sternberg will discuss the company’s ophthalmic therapies for eye diseases, including open-angle glaucoma and diabetic macular edema. The event will be webcasted and available for replay until July 11, 2022. Learn more about Aerie's products, Rhopressa® and Rocklatan®, which are FDA-approved treatments for elevated intraocular pressure.
Aerie Pharmaceuticals (NASDAQ: AERI) announces the appointment of Peter F. Lang as Chief Financial Officer, effective March 18, 2022. Lang brings over 25 years of experience in finance, capital management, and strategy, having raised approximately $105 billion in financing and advised on over $25 billion in M&A transactions. CEO Raj Kannan expressed confidence in Lang’s ability to enhance shareholder value through his expertise in the biopharma sector. Lang joins Aerie from Ridge Advisory, having previously held positions at notable investment banks.
Aerie Pharmaceuticals (NASDAQ: AERI) announced strong financial results for 2021, reporting total net revenues of $194.1 million, a 133% increase from 2020. The glaucoma franchise generated $112.1 million in net revenues, up 35%, with Q4 revenues of $32.7 million, an 11% increase from Q3. Net income for 2021 reached $45.5 million, contrasting with a net loss of $46.1 million in 2020. The company forecasts 2022 glaucoma franchise revenues between $130 million and $140 million, expecting 16% to 25% growth. Aerie also plans to initiate three Phase 3 studies for AR-15512.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has appointed Gary Sternberg, M.D., M.B.A., as Chief Medical Officer, effective March 1, 2022. Dr. Sternberg is an experienced ophthalmologist and biopharmaceutical executive, bringing over 20 years in clinical development, strategy, and business development. CEO Raj Kannan expressed confidence in his ability to enhance the company’s clinical portfolio and global profile. Dr. Sternberg emphasizes the potential of Aerie’s pipeline to transform patient care in ophthalmology.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. A live conference call will follow at 5:00 p.m. ET to discuss the results and provide a business update. Aerie focuses on developing first-in-class ophthalmic therapies for conditions such as open-angle glaucoma and dry eye. Key products include Rhopressa and Rocklatan, both aimed at reducing elevated intraocular pressure.
